23andMe CEO Anne Wojcicki’s vision for changing healthcare as a ‘full-fledged biotech’
In the 17 years since its launch, 23andMe has cemented its foothold in the at-home genetic testing market. But along the way, the company has also realized its long-term vision of becoming a full-fledged biotech. It’s just that the rest of the industry hasn’t fully caught on, according to Anne Wojcicki, the company’s co-founder and CEO.
“I’ve talked to all kinds of people over the last year who stare at me [thinking] … you do research?” she said.
She assures them that yes, 23andMe does real novel drug research in real labs.
“We have real labs,” she said. “Scientists, pipettes. Doing functional genomics experiments. We have 100 people doing therapeutics research. We have gone entirely from genetic data, hypothesis, early research, to filing an IND and actually in human studies with a phase 2a program.”
In fact, 23andMe’s pipeline includes two clinical programs, both in immuno-oncology, and more in the discovery and preclinical phases in immuno-oncology, cardiovascular/metabolic, immunology and neurology.
But it shouldn’t be a surprise to anyone who paid close attention when the company launched in 2006; or when it hired R&D veteran Richard Scheller as head of therapeutics and chief scientific officer in 2015; or when it got the official nod in 2017 to market the first FDA-authorized, direct-to-consumer tests to determine genetic predisposition to certain medical diseases or conditions; or just last month when the company extended a data licensing collaboration with GSK for drug target discovery and other research.
“The goal has always been: How are we empowering individuals and how are we changing the trajectory of healthcare?”
Anne Wojcicki
CEO, founder, 23andMe
“From day one, it was set up to be a database you could leverage for research,” Wojcicki said. Indeed, she said that the company’s data is not only useful in portfolio validation for its partners, but that the size and scale of its data “swamps” many other resources. Compare, for instance, the UK Biobank’s data on 550,000 people to 23andMe’s insights on more than 14 million.
She also touts the “breadth of phenotyping,” since 23andMe asks its customers questions that go beyond the medical record, like, “Do you cry when you cut onions?”
Throughout the company’s evolution Wojcicki has been a rising force in Silicon Valley, and has been surrounded by them, too. One of her sisters, Susan Wojcicki, was the CEO of YouTube from 2014 until early 2023 and her ex-husband is Google co-founder Sergey Brin. She’s also one of the co-founders of the Breakthrough Prize in Life Sciences along with Brin; Mark Zuckerberg and Priscilla Chan; and investor and entrepreneur Yuri Milner.
And with the spotlight on them, 23andMe hasn’t been without controversy. From data privacy concerns to the possibility of discrimination based on genetic information, the company has been navigating a host of ethical concerns. It’s also currently embroiled in a breach of customer user data. Now, Connecticut Attorney General William Tong is asking the company for more details, including whether the breach specifically targeted people of Ashkenazi Jewish and Chinese heritage.
“The increased frequency of antisemitic and anti-Asian rhetoric and violence in recent years means that this may be a particularly dangerous time for such targeted information to be released to the public,” Tong wrote in an inquiry letter to the company.
Yet for all those hurdles, 23andMe hasn’t slowed its march deeper into its users’ health and lives. Recently, it launched its Health Action Plan tool, which provides health recommendations based on personal genetic reports, health history survey data and blood and biomarker data. 23andMe also sells the first and only direct-to-consumer, FDA-authorized pharmacogenetics reports that tell people their likelihood of developing side effects from specific drugs. It also launched a genetic report on a commonly prescribed statin in June.
And Wojcicki hopes that all the data they’ve collected will come “full circle” to help the very people who contributed their information to the drug discovery process.
“The No. 1 reward I can imagine is, at some point, we have a therapy that benefits our customers,” she said.
She also thinks that genomics could and should transform the country’s entire approach to healthcare
“I think everyone should have their genome on day one, and healthcare should be built around prevention,” she said.
In a sit-down interview with PharmaVoice, Wojcicki described the company’s ongoing transformation, its collaborations with pharma companies and surprises she’s encountered along the way.
This interview has been edited for brevity and style.
PHARMAVOICE: Why is 23andMe in a good position for novel drug development?
ANNE WOJCICKI: We have always been a consumer company, but the goal has always been: How are we empowering individuals and how are we changing the trajectory of healthcare? And change it from empowering individuals to get access to their own genetic information as well as changing by helping leverage crowdsourcing data so that we can cure disease.
Part of the responsibility we have to our customers [in] dramatically accelerating the pace of research is being able to leverage the insights we have for their good. Obviously we do that on the consumer side in returning the reports, but we also felt like we needed to [make] our best attempt at saying, let’s see if we can actually solve these problems.
When we had the opportunity to hire Richard Scheller, that was the beginning of the transition of 23andMe from more of a consumer company into a true healthcare company, and that was not well understood by the industry. Then, in 2018, we did a large collaboration with GSK. And if you look at everything we did and all the announcements we had…it really showed we became a full-fledged biotech.
23andMe CEO Anne Wojcicki speaks on stage during ‘The Fast Company Innovation Festival’ – Data + Drugs: The New Evolution Of Drug Making With 23andMe And Sprout in 2015.
Brad Barket via Getty Images
We have a consumer division that focuses on engaging the consumer. But we also have a very large therapeutic side that’s focused on how we’re going to translate this data to the benefit of our customers. We have our immuno-oncology programs in house and we have a dedicated discovery team focused on inflammation and immunology and looking at how we [can] go through datasets, pull out interesting and novel insights, and translate those into meaningful discoveries and cures potentially for our customers.
You started 23andMe with your co-founders as a response to the way the U.S. health system is incentivized toward illness. Has your perceptions of that system changed since then and do you think 23andMe has moved the needle to change that in any way?
There’s [a lot] I’m proud of with the company, and one thing that’s put us on the map is the whole world of direct to consumer. Prior to us, you had OTC products that you could buy, but there wasn’t really a direct-to-consumer industry for healthcare. And obviously, the entire industry exploded during the pandemic because of telemedicine and those opportunities.
Also along those lines, we have proven that there are aspects of healthcare, like your genome, where you don’t necessarily have to go through a healthcare provider — our FDA authorizations are direct to consumer — that do not require pre-counseling or post-counseling.
One of the most important aspects of healthcare, long term, is being able to prove that to deliver care in any kind of scalable way, it cannot be dependent on an interaction of one-to-one between a consumer and a physician. You have to find ways that healthcare can scale. [Other] industries all scale because they have found out how to do that without having to have a one-to-one interaction. So we’ve been able to deliver genetic data now to 14 million people and none of those customers had pre-counseling or post-counseling. They may have taken some of that data to their clinicians to follow up or to chat about it, but they were able to get that in an affordable and efficient manner.
I do also look at the millions of my customers who have learned lifesaving or life-changing information, and the impact that has had. We have opened up a new industry. We’ve had a profound impact on customers’ lives.
You said that from the beginning 23andMe was set up as a database for research. Has the way the company’s grown always been part of the bigger picture? And are there directions that the company has gone that have surprised you, like solving cold cases?
We had a really good set of advisors early on, and we spent a lot of time on ethics. It’s unusual because as a startup tech company, we had consent forms right away and we spent lots of time soliciting feedback on consent and on getting input. We had a scientific advisory group [that] pontificated about…all the crazy things that could happen, and solving cold cases was one of them. So I feel grateful for the team that helped us think through a lot of it … and we were well prepared for a lot of the issues that came our way.
[What] has always surprised me is just how well the machine works, meaning that self-report works really well; most people want to opt into research; and most people when I re-contacted them and they see the message, they are interested in participating in research. So our ability to create this real-time research engine has really been extraordinary.
“The whole biotech/pharma industry still hasn’t quite grasped how much people want to be participants and partners in healthcare.”
Anne Wojcicki
CEO, founder, 23andMe
The one area I was not prepared as much for was that we would be front and center on the conversation around race. Like, what’s the definition of African American? At what percentage of African DNA are you no longer African American? Those are the types of ethical questions that I didn’t anticipate. We had people who were white supremacists doing 23andMe and finding out that they are not as white and European as they expected and that they were more diverse and that changed them. We always anticipated a lot on the health side, and we spent a lot of time on the ethics of the health side. But … the sense that your genome impacts your sense of identity was an area that surprised me more. And just how much it changes that sense of identity.
What are some things that the company hasn’t touched yet? Where else could you expand?
I’m always surprised that genetics is not well adopted in clinical trials because you can use genetics to pick the right population to recruit a clinical study. The whole biotech/pharma industry still hasn’t quite grasped how much people want to be participants and partners in healthcare. They don’t want to just be a subject. People actually want to have a voice and they want to have a meaningful voice. There’s a real opportunity for us to have the real-world evidence and … engage people.
Some have raised concerns that insurance companies could use genetic information to deny coverage. How do you allay those fears?
Health information coverage is protected under GINA, the Genetic Information Nondiscrimination Act, so you’re protected there. We’re 17 years old, and I haven’t heard about [insurance companies] using it in any capacity for deciding coverage. Rather I’ve heard more that there’s an interest in how [to] use genetics to help people be healthier. Rather [than being denied coverage] I’ve seen the opposite. I find that people find out they have APOE e4 — they have a higher risk for Alzheimer’s — and they want to be proactive, and they go out and they get long-term care insurance, things like that.
How did 23andMe decide that direct to consumer was the correct route for this when it had never been done before?
One of the areas that I was investing in that I was most impressed with [as a healthcare investment analyst] was the HIV community. I started going to all the disease advocacy group meetings [like] Project Inform and Gay Men’s Health Crisis. They were super aware. They were better than all my Wall Street research. They knew what was coming, they knew the side effects [of drugs]. The community was self-reporting. I was blown away that this community had taken charge, and I felt like I was learning from them.
At the same time you had the Live Strong communities, and you had Susan G. Komen, and you had all these people showing up for these three-day walks, and people were constantly asking to donate. I realized there’s this huge opportunity to engage people. I would be in these meetings … around genetics or around access to medical records, and I remember thinking, who owns the data? There’d be these turf wars. It’s the hospital or it’s the doctor or the provider, the insurer, and no one ever talked about patients.
“I went to one meeting about billing optimization … packed with people in suits. And I realized the world was focused on revenue optimization and not on dramatic changes to keep you and me healthier.”
Anne Wojcicki
CEO, founder, 23andMe
I saw from Livestrong and Susan G. Komen there was enthusiasm for people to make a difference. I saw from the HIV world that people could actually step up and crowdsource research and make a difference. And I realized … all this could go online. Just crowdsource a revolution online.
And I also had this moment where [in] 2004, 2006 the markets were tough. I felt like innovation had dried up. I went to this one meeting in D.C. about billing optimization … It was this room packed with people in suits. And I realized the world was focused on revenue optimization and not on dramatic changes to keep you and me healthier. That’s when I decided the world’s never going to change from within. If you want to change healthcare, you have to change it from outside. I still, to this day, stand by it. I don’t think you change from within because the incentives are just wrong. And every time I ask that question, ‘Who profits if I stay healthy?’ no one has an answer for me. There’s no one who makes money if I stay healthy.
Do you still feel that 23andMe is on the outside of the healthcare system?
I feel like we are getting closer. For a while we were on the outside, and some of the worst things our competitors did was coin the term ‘recreational genomics,’ which was just awful, [as though all we] do [are] cilantro studies and Neanderthal [reports]. But we were also so dangerous that we had to be shut down and regulated. It really confused people.
At the end of the day, we’re consumer-empowering. Is APOE e4 for Alzheimer’s risk…just recreational information? It changes people’s lifestyles. It’s absolutely about your quality of life … and helping [people] make long term decisions.
After 17 years, we’re getting closer and closer with our FDA authorizations and our general acceptance. We have also been running surveys of clinicians, and we now can see that physicians are interested in genetic information. They would like to offer genetic information to their patients, and they’re just not trained on it.
And I am the most optimistic I’ve ever been in terms of the ability for there to be a direct-to-consumer world that can be a partner to the traditional insured world. You go to your doctor episodically. I go to the doctor three days a year, and the other 362 days, I’m living my life. So there has to, ideally, be a partnership between how I actually live my life and what I do the four hours a year I’m at the doctor. Long term, it’s important that there’s some kind of hybrid connection between what consumers are doing in the direct-to-consumer world and what the medical world is doing.
Source link
#23andMe #CEO #Anne #Wojcickis #vision #changing #healthcare #fullfledged #biotech
